ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Biotechnology

2 regenerative medicines set for swift green light in Japan

Japan may approve Terumo's "heart sheet" regenerative treatment for heart failure this month.

TOKYO -- Two new regenerative medicine products are expected to receive approval from Japan's health ministry as early as this month, just a year after applications were filed.

     Terumo's heart failure treatment "heart sheet" and JCR Pharmaceuticals' treatment for complications linked to bone marrow transplants may hit the market this year. These would be the first regenerative medicines to get the green light in Japan after regulations were revamped last November to accelerate such approvals. JCR Pharma applied in September 2014 and Terumo a month later, in view of the regulatory update underway.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more